Aerovate Total Current Liabilities from 2010 to 2024
| AVTE Stock | USD 2.32 0.04 1.69% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 17.6 M | Current Value 18.5 M | Quarterly Volatility 6.1 M |
Check Aerovate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aerovate Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 5.4 M, Depreciation And Amortization of 100.8 K or Selling General Administrative of 9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.72. Aerovate financial statements analysis is a perfect complement when working with Aerovate Therapeutics Valuation or Volatility modules.
Aerovate | Total Current Liabilities |
Latest Aerovate Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Aerovate Therapeutics over the last few years. Total Current Liabilities is an item on Aerovate Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Aerovate Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Aerovate Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aerovate Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Aerovate Total Current Liabilities Regression Statistics
| Arithmetic Mean | 3,655,457 | |
| Geometric Mean | 1,409,565 | |
| Coefficient Of Variation | 168.02 | |
| Mean Deviation | 4,396,197 | |
| Median | 657,000 | |
| Standard Deviation | 6,141,787 | |
| Sample Variance | 37.7T | |
| Range | 17.9M | |
| R-Value | 0.71 | |
| Mean Square Error | 20.1T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 976,646 | |
| Total Sum of Squares | 528.1T |
Aerovate Total Current Liabilities History
About Aerovate Therapeutics Financial Statements
Aerovate Therapeutics stakeholders use historical fundamental indicators, such as Aerovate Therapeutics' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Aerovate Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aerovate Therapeutics' assets and liabilities are reflected in the revenues and expenses on Aerovate Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aerovate Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 17.6 M | 18.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Check out the analysis of Aerovate Therapeutics Correlation against competitors. For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.44) | Return On Equity (0.74) |
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.